Conclusion

The growth of the aging population, regulatory overview and increased business opportunities will ensure the growth of clinical research in the elderly. Recent reports of the high level of seniors' adverse events, many leading to deaths, both in and outside hospitals, will force more monitoring systems for medications. Soon, plastic medicine card chips with imprinted medication recorded by the pharmacist will be required by third-party insurers. This would ensure that all current concurrent medications are captured.

There is a shortage of geriatric specialists, which will take time to be corrected if the 600 drugs under development are to be adequately researched. The rapid growth of sheltered self-care communal housing for active seniors, which guarantee health care up to terminal status, illustrates that seniors wish to stay out of nursing homes. Their expectation of the pharmaceutical industry is that it should provide them with medications which allow for an active old age. The industry has heard.

0 0

Post a comment